TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04425915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Dose-250 ml Frequency - 2 doses on consecutive days Duration -Start by day 3 of symptom onset (of severe COVID-19 as in inclusion criteria) in eligible patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)
Study: NCT02591836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene
Study: NCT02873000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry
Description: Incentive Spirometer is a tool that allows for deep breathing in a controlled setting while providing the user with visual feedback demonstrating the inspiratory volume of each breath.
Study: NCT00705198

Intervention type: DRUG
Intervention: Temozolomide (for newly diagnosed malignant glioma)
Description: Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules.

Intervention type: DRUG
Intervention: Temozolomide (for newly diagnosed malignant glioma)
Description: Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules.

Intervention type: DRUG
Intervention: Temozolomide (for relapsed malignant glioma)
Description: Temozolomide treatment for relapsed malignant glioma. The usual dose for adults is 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules.

Intervention type: RADIATION
Intervention: Radiotherapy (for patients with newly diagnosed malignant glioma)
Description: Although the study protocol does not clearly define how long this intervention is applied, radiotherapy is generally administered 5 days/week for 6 weeks to patients with newly diagnosed malignant glioma.

Intervention type: RADIATION
Intervention: Radiotherapy (for patients with newly diagnosed malignant glioma)
Description: Although the study protocol does not clearly define how long this intervention is applied, radiotherapy is generally administered 5 days/week for 6 weeks to patients with newly diagnosed malignant glioma.
Study: NCT03123718

Intervention type: DRUG
Group type: OTHER
Intervention: Intrathecal methotrexate
Description: Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
Study: NCT02591836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04071808

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA Test
Description: The levels of orphanin and norepinephrine in blood of diabetic patients with painless myocardial ischemia requiring interventional therapy and diabetic patients without interventional therapy were measured.
Study: NCT00123474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 50 mg BID, indefinitely, survival study
Study: NCT03975049

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: Fluorouracil 225 mg/m2/day continuous intravenous infusion on weekdays for five weeks; local irradiation 2GY/day on weekdays, totally 50GY.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI Protocol
Description: Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic G-CSF support is recommended.
Study: NCT00931710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan, amlodipine, HCTZ
Description: combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
Description: losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study
Study: NCT03975049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox Protocol
Description: Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.
Study: NCT01238042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: 3mg/m2 or 4 mg/m2 at light doses of 150, 175 and 200 joules/cm
Study: NCT00774397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA 240 mg QD / LI
Description: 240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks
Study: NCT03080532

Intervention type: OTHER
Intervention: dietary habits
Study: NCT04426240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine microemulsion
Description: Intervention group receives topical cyclosporine dry eye treatment before cataract surgery
Study: NCT00774397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Description: PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA 120mg QD / LI
Description: 120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Description: PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA 240 mg QD
Description: 240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
Study: NCT01681836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15Nitrogen(15N)-labeled sodium nitrite
Description: 15Nitrogen(15N)-labeled sodium nitrite 20 mg once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15Nitrogen(15N)-labeled sodium nitrite
Description: 15Nitrogen(15N)-labeled sodium nitrite 20 mg once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15Nitrogen(15N)-labeled sodium nitrate
Description: 15Nitrogen(15N)-labeled sodium nitrate 1,000 mg once
Study: NCT00774397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Description: PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA 240 mg QD
Description: 240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
Study: NCT00123474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 70 mg BID, indefinitely, survival study
Study: NCT03123718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose intravenous methotrexate
Description: Intravenous administration of 1st and 2nd doses of methotrexate 3g/m2 on day 15 of 2nd and 6th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.~\* Dose of intravenous methotrexate will be reduced to 2g/m2 for patients aged \>70 years.
Study: NCT03809052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: Hard capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: Hard capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: Hard capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: Hard capsules for oral use
Study: NCT00774397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Description: PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
Study: NCT00123474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 100 mg QD, indefinitely, survival study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 140 mg QD, indefinitely, survival study
Study: NCT00774397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA 240 mg BID
Description: 240mg BI 201335 NA (Faldaprevir) twice, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Description: PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Description: PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA 240 mg QD
Description: 240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PegIFN/RBV
Description: PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02930200

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Tobacco Treatment Research Program (TTRP) or Treatment as Usual (TAU)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: QuitGuide
Description: NCI QuitGuide Treatment App

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart-T
Description: Smart-Treatment App
Study: NCT00810849

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Mycobacterium w immunotherapy
Description: Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months). Patients in the control arm of the Mycobacterium w comparison will receive a similar regime of placebo injections of normal saline in identically-packaged vials.
Study: NCT01171118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physostigmine
Description: Physostigmine is a centrally acting acetylcholinesterase inhibitor that has been proposed as a treatment for sleep disordered breathing. It is currently FDA approved and used commonly by Anesthesiologists in the post anesthetic setting to reverse confusion caused by central anticholinergic medication effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physostigmine
Description: Physostigmine is a centrally acting acetylcholinesterase inhibitor that has been proposed as a treatment for sleep disordered breathing. It is currently FDA approved and used commonly by Anesthesiologists in the post anesthetic setting to reverse confusion caused by central anticholinergic medication effects.
Study: NCT04551963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Capsules administered at a dose and frequency as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Capsules administered at a dose and frequency as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Capsules administered at a dose and frequency as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Capsules administered at a dose and frequency as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Capsules administered at a dose and frequency as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Capsules administered at a dose and frequency as specified in the treatment arm
Study: NCT00529776

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous lateral rotation therapy
Study: NCT00974506

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAM-intervention
Description: Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine care therapy by general practitioner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care therapy
Description: Routine care therapy by general practitioner
Study: NCT02905799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral resveratrol
Description: Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo
Description: Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months
Study: NCT03569878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Integrated Multidisciplinary Collaborative Care
Description: Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
Study: NCT03809052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: Hard capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: Hard capsules for oral use
Study: NCT01655563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus, a calcineurin inhibitor, is the commonest immunosuppressive agent used for maintenance immunosuppression after solid organ transplantation. The mechanism of action involves binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the generation of nuclear factor of activated T-cells, a nuclear component, resulting in inhibition of transcription of lymphokines (interleukin-2, γ-interferon). The net result is the inhibition of T-lymphocyte activation.Tacrolimus is metabolized primarily by the CYP3A enzymes in the liver particularly the CYP3A5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus, a calcineurin inhibitor, is the commonest immunosuppressive agent used for maintenance immunosuppression after solid organ transplantation. The mechanism of action involves binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the generation of nuclear factor of activated T-cells, a nuclear component, resulting in inhibition of transcription of lymphokines (interleukin-2, γ-interferon). The net result is the inhibition of T-lymphocyte activation.Tacrolimus is metabolized primarily by the CYP3A enzymes in the liver particularly the CYP3A5.
Study: NCT02187536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan placebo
Study: NCT03167944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low thermal electrosurgery system
Description: PEAK Plasmablade

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Electrocautery
Description: Conventional Electrocautery
Study: NCT02917512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU00701
Description: Cyclosporine 0.01% + 3% trehalose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU007
Description: Cyclosporine 0.02% + 3% trehalose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Description: Cyclosporine 0.05%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study: NCT01488734

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mushroom with 600 IU vitamin D2
Description: Subjects in this group will eat daily meals containing mushrooms fortified with 600 IU of Vitamin D2. These subjects will also take one placebo tablet per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mushroom with 4000 IU Vitamin D2
Description: Subjects in this group will eat daily meals containing mushrooms fortified with 4000 IU of Vitamin D2. These subjects will also take one placebo tablet per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 600 IU Vitamin D3 and untreated mushroom
Description: Subjects in this group will take one commercially available tablet of 600 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4000 IU Vitamin D3 and untreated mushroom
Description: Subjects in this group will take one commercially available tablet of 4000 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for the fortified mushroom arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for the fortified mushroom arms
Study: NCT02056236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-epileptic drugs
Description: Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.~The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No anti-epileptic drugs
Description: The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented.
Study: NCT02292004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACL Repair with MIACH Scaffold
Description: Surgical insertion of the MIACH scaffold to promote ACL healing/repair
Study: NCT03569878

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma surgery team notification
Description: Trauma surgery team notification of patient emotional distress, with plan for mental health inpatient consultation will be the comparator condition.
Study: NCT04098653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine was administered at 20mg/m2/day on days -14 and -10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT03378544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mhGAP
Description: The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity